Back to Search
Start Over
Effects of oral N-acetylcysteine on walking capacity, leg reactive hyperemia, and inflammatory and angiogenic mediators in patients with intermittent claudication.
- Source :
-
American journal of physiology. Heart and circulatory physiology [Am J Physiol Heart Circ Physiol] 2015 Sep; Vol. 309 (5), pp. H897-905. Date of Electronic Publication: 2015 Jun 26. - Publication Year :
- 2015
-
Abstract
- Increased oxidative stress and inflammation contribute to impaired walking capacity and endothelial dysfunction in patients with intermittent claudication (IC). The goal of the study was to determine the effects of oral treatment with the antioxidant N-acetylcysteine (NAC) on walking capacity, leg postocclusive reactive hyperemia, circulating levels of inflammatory mediators, and whole blood expression of angiogenic mediators in patients with IC. Following a double-blinded randomized crossover design, 10 patients with IC received NAC (1,800 mg/day for 4 days plus 2,700 mg before the experimental session) and placebo (PLA) before undergoing a graded treadmill exercise test. Leg postocclusive reactive hyperemia was assessed before and after the test. Blood samples were taken before and after NAC or PLA ingestions and 5 and 30 min after the exercise test for the analysis of circulating inflammatory and angiogenic markers. Although NAC increased the plasma ratio of reduced to oxidized glutathione, there were no differences between experimental sessions for walking tolerance and postocclusive reactive hyperemia. Plasma concentrations of soluble vascular cell adhesion protein-1, monocyte chemotactic protein-1, and endothelin-1 increased similarly following maximal exercise after PLA and NAC (P < 0.001). Whole blood expression of pro-angiogenic microRNA-126 increased after maximal exercise in the PLA session, but treatment with NAC prevented this response. Similarly, exercise-induced changes in whole blood expression of VEGF, endothelial nitric oxide synthase and phosphatidylinositol 3-kinase R2 were blunted after NAC. In conclusion, oral NAC does not increase walking tolerance or leg blood flow in patients with IC. In addition, oral NAC prevents maximal exercise-induced increase in the expression of circulating microRNA-126 and other angiogenic mediators in patients with IC.<br /> (Copyright © 2015 the American Physiological Society.)
- Subjects :
- Acetylcysteine administration & dosage
Administration, Oral
Aged
Antioxidants administration & dosage
Chemokine CCL2 blood
Endothelins blood
Humans
Hyperemia blood
Inflammation blood
Inflammation drug therapy
Intermittent Claudication blood
Leg blood supply
Male
MicroRNAs blood
Middle Aged
Nitric Oxide Synthase Type III blood
Phosphatidylinositol 3-Kinases blood
Vascular Cell Adhesion Molecule-1 blood
Vascular Endothelial Growth Factor A blood
Acetylcysteine therapeutic use
Antioxidants therapeutic use
Hyperemia drug therapy
Intermittent Claudication drug therapy
Walking
Subjects
Details
- Language :
- English
- ISSN :
- 1522-1539
- Volume :
- 309
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- American journal of physiology. Heart and circulatory physiology
- Publication Type :
- Academic Journal
- Accession number :
- 26116711
- Full Text :
- https://doi.org/10.1152/ajpheart.00158.2015